Functional Characterization of a Lassa Virus Fusion Inhibitor Adaptive Mutant

Abstract

Objective: Lassa virus (LASV) glycoprotein complex (GPC) contains retained stable-signal peptide (SSP), glycoprotein 1 (GP1), and glycoprotein 2 (GP2). Through serial passaging of LASV with inhibitors, adaptive mutants were obtained, most of which had mutations in the transmembrane (TM) domain of GP2. Characterizing the fusion inhibitor target within the TM domain of GP2 provided insights for the development of drugs and vaccines.

Methods: We conducted membrane fusion, IIH6 inhibition, thermostability, and viral growth kinetics assays to characterize the effects of the F446L mutation on GPC-mediated membrane fusion, receptor binding, thermostability, growth kinetics, and fitness.

Results: F446L conferred cross-resistance to structurally distinct inhibitors. Additionally, F446L increased the fusion activity of LASV and Mopeia virus (MOPV) GPC, thus elevating the pH threshold for LASV fusion and promoting MOPV fusion at neutral pH. However, F446L exerted little effect on the pseudotype viral growth profile or thermostability. Introduction of other residues at the conserved F446 locus indicated that this site showed low compatibility with similar retained aromatic cyclic tyrosine residues and did not tolerate charged residues.

Conclusions: We characterized the effects of the F446L mutation on LASV, thus providing useful information for the development of vaccines and drugs.

Keywords

Lassa virus (LASV) / glycoprotein complex (GPC) / fusion inhibitor / adaptive mutant / membrane fusion

References

[1] Wang W, Zhou Z, Zhang L, Wang S, Xiao G. Structure-function relationship of the mammarenavirus envelope glycoprotein. Virol Sin. 2016; 31: 380-394.

[2] Maes P, Alkhovsky SV, Bao Y, Beer M, Birkhead M, Briese T, et al. Taxonomy of the family Arenaviridae and the order Bunyavirales: update 2018. Arch Virol. 2018; 163: 2295-2310.

[3] Buchmeier MJ, de la Torre JC, Peters CJ. Fields Virology . 4th edition. Philadelphia: Lippincott-Raven; 2007: 1791-1828.

[4] Vela E. Animal models, prophylaxis, and therapeutics for arenavirus infections. Viruses. 2012; 4: 1802-1829.

[5] Shankar S, Whitby LR, Casquilho-Gray HE, York J, Boger DL, Nunberg JH. Small-molecule fusion inhibitors bind the pH-sensing stable signal peptide-GP2 subunit interface of the Lassa virus envelope glycoprotein. J Virol. 2016; 90: 6799-6807.

[6] Wang P, Liu Y, Zhang G, Wang S, Guo J, Cao J, et al. Screening and identification of Lassa virus entry inhibitors from an FDA-approved drugs library. J Virol. 2018; 92: e00954-18.

[7] Tang K, Zhang X, Guo Y. Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry. Acta Pharm Sin B. 2020; 10: 789-798.

[8] Katz M, Weinstein J, Eilon-Ashkenazy M, Gehring K, Cohen-Dvashi H, Elad N, et al. Structure and receptor recognition by the Lassa virus spike complex. Nature. 2022; 603: 174-179.

[9] York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol. 2008; 82: 10932-10939.

[10] Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005; 2: e183.

[11] Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis. 2015; 9: e0003736.

[12] Takikawa S, Ishii K, Aizaki H, Suzuki T, Asakura H, Matsuura Y, et al. Cell fusion activity of hepatitis C virus envelope proteins. J Virol. 2000; 74: 5066-5074.

[13] Thomas CJ, Casquilho-Gray HE, York J, DeCamp DL, Dai D, Petrilli EB, et al. A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junin hemorrhagic fever arenavirus. J Biol Chem. 2011; 286: 6192-6200.

[14] Cao J, Zhang G, Zhou M, Liu Y, Xiao G, Wang W. Characterizing the Lassa virus envelope glycoprotein membrane proximal external region for its role in fusogenicity. Virol Sin. 2020; 36: 273-280.

[15] Moraz ML, Pythoud C, Turk R, Rothenberger S, Pasquato A, Campbell KP, et al. Cell entry of Lassa virus induces tyrosine phosphorylation of dystroglycan. Cell Microbiol. 2013; 15: 689-700.

[16] Oppliger J, Torriani G, Herrador A, Kunz S. Lassa virus cell entry via dystroglycan involves an unusual pathway of macropinocytosis. J Virol. 2016; 90: 6412-6429.

[17] Wang MK, Lim SY, Lee SM, Cunningham JM. Biochemical basis for increased activity of Ebola glycoprotein in the 2013-16 epidemic. Cell Host Microbe. 2017; 21: 367-375.

[18] Li P, Shan Y, Zheng W, Ou X, Mi D, Mu Z, et al. Identification of H209 as essential for pH 8-triggered receptor-independent syncytium formation by S protein of mouse hepatitis virus A59. J Virol. 2018; 92: e00209-18.

[19] Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, et al. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever new world arenaviruses. Antiviral Res. 2006; 69: 86-97.

[20] Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008; 82: 10768-10775.

[21] Zhang G, Cao J, Cai Y, Liu Y, Li Y, Wang P, et al. Structure-activity relationship optimization for Lassa virus fusion inhibitors targeting the transmembrane domain of GP2. Protein Cell. 2019; 10: 137-142.

[22] Zhang Z, Takenaga T, Fehling SK, Igarashi M, Hirokawa T, Muramoto Y, et al. Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry. J Virol. 2024; 98: e0071424.

[23] Glushakova SE, Lukashevich IS. Early events in arenavirus replication are sensitive to lysosomotropic compounds. Arch Virol. 1989; 104: 157-161.

[24] Cao W, Henry MD, Borrow P, Yamada H, Elder JH, Ravkov EV, et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science. 1998; 282: 2079-2081.

[25] Jae LT, Raaben M, Herbert AS, Kuehne AI, Wirchnianski AS, Soh TK, et al. Virus entry. Lassa virus entry requires a trigger-induced receptor switch. Science. 2014; 344: 1506-1510.

[26] Garry RF. Lassa fever - the road ahead. Nat Rev Microbiol. 2023; 21: 87-96.

[27] Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020; 370: 1464-1468.

[28] Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020; 182: 812-827.e19.

[29] Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020; 592: 116-121.

[30] Diehl WE, Lin AE, Grubaugh ND, Carvalho LM, Kim K, Kyawe PP, et al. Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 epidemic. Cell. 2016; 167: 1088-1098.e6.

[31] Siddle KJ, Eromon P, Barnes KG, Mehta S, Oguzie JU, Odia I, et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N Engl J Med. 2018; 379: 1745-1753.

[32] Albariño CG, Bird BH, Chakrabarti AK, Dodd KA, Flint M, Bergeron E, et al. The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J Virol. 2011; 85: 10404-10408.

[33] Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, et al. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol. 2011; 85: 13457-13462.

[34] Madu IG, Files M, Gharaibeh DN, Moore AL, Jung KH, Gowen BB, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018; 14: e1007439.

[35] Patterson M, Koma T, Seregin A, Huang C, Miller M, Smith J, et al. A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of Machupo virus. J Virol. 2014; 88: 10995-10999.

[36] Wang S, Liu Y, Guo J, Wang P, Zhang L, Xiao G, et al. Screening of FDA-approved drugs for inhibitors of Japanese Encephalitis virus infection. J Virol. 2017; 91: e01055-17.

[37] Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog. 2014; 10: e1003831.

[38] Di Lella S, Herrmann A, Mair CM. Modulation of the pH stability of influenza virus hemagglutinin: a host cell adaptation strategy. Biophys J. 2016; 110: 2293-2301.

[39] Wang W, Song HS, Keller PW, Alvarado-Facundo E, Vassell R, Weiss CD. Conformational stability of the hemagglutinin of H5N1 influenza a viruses influences susceptibility to broadly neutralizing stem antibodies. J Virol. 2018; 92: e00247-18.